Cargando…

A comparative study of orphan drug prices in Europe

Background and Objective: This study assessed price differences by comparing annual treatment costs of similarly available orphan drugs in France, Germany, Italy, Norway, Spain, Sweden, and UK. Methods: Annual treatment costs per drug were calculated using ex-factory prices from IHS POLI and country...

Descripción completa

Detalles Bibliográficos
Autores principales:	Young, Katherine Eve, Soussi, Imen, Hemels, Michiel, Toumi, Mondher
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Routledge 2017
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5405561/ https://www.ncbi.nlm.nih.gov/pubmed/28473887 http://dx.doi.org/10.1080/20016689.2017.1297886

Ejemplares similares

Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe
por: Medic, Goran, et al.
Publicado: (2017)

Determinants of orphan drugs prices in France: a regression analysis
por: Korchagina, Daria, et al.
Publicado: (2017)

The perverse impact of external reference pricing (ERP): a comparison of orphan drugs affordability in 12 European countries. A call for policy change
por: Young, K. E., et al.
Publicado: (2017)

Overview of external reference pricing systems in Europe
por: Rémuzat, Cécile, et al.
Publicado: (2015)

Quantifying the persisting orphan-drug shortage public health crisis in the United States
por: Jarosławski, Szymon, et al.
Publicado: (2016)

Patient-reported outcome claims in European and United States orphan drug approvals
por: Jarosławski, Szymon, et al.
Publicado: (2018)

Low rates of patient-reported outcome claims for orphan drugs approved by the us food and drug administration
por: Jarosławski, Szymon, et al.
Publicado: (2018)

Pricing of orphan drugs in oncology and rare diseases
por: Nuijten, Mark, et al.
Publicado: (2020)

The impact of early phase price agreements on prices of orphan drugs
por: Nuijten, Mark, et al.
Publicado: (2021)

Establishing a reasonable price for an orphan drug
por: Berdud, Mikel, et al.
Publicado: (2020)

Pharmaceutical pricing and reimbursement policies in Algeria, Morocco, and Tunisia: comparative analysis
por: Dahmani, Hajer, et al.
Publicado: (2023)

Variables affecting pricing of orphan drugs: the Italian case
por: Jommi, Claudio, et al.
Publicado: (2021)

Social Preferences for Orphan Drugs: A Discrete Choice Experiment Among the French General Population
por: Toumi, Mondher, et al.
Publicado: (2020)

Orphan drugs’ clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan drug reimbursement
por: Eichler, Hans-Georg, et al.
Publicado: (2023)

President Trump’s prescription to reduce drug prices: from the campaign trail to American Patients First
por: Dabbous, Monique, et al.
Publicado: (2019)

Orphan Drug Pricing and Costs: A Case Study of Kalydeco and Orkambi
por: Hollis, Aidan
Publicado: (2019)

Drug pricing reform in China: analysis of piloted approaches and potential impact of the reform
por: Chen, Yixi, et al.
Publicado: (2016)

Shining a light in the black box of orphan drug pricing
por: Picavet, Eline, et al.
Publicado: (2014)

Orphan Drug Pricing: An Original Exponential Model Relating Price to the Number of Patients
por: Messori, Andrea
Publicado: (2016)

Pricing and reimbursement of orphan drugs: the need for more transparency
por: Simoens, Steven
Publicado: (2011)

Comparing access to orphan medicinal products in Europe
por: Zamora, Bernarda, et al.
Publicado: (2019)

The real-life impact of vaccination on COVID-19 mortality in Europe and Israel
por: Jabłońska, Katarzyna, et al.
Publicado: (2021)

The actual status of drug prices and adjustment factors for drug price calculation: an analysis of ultra-orphan drug development in Japan
por: Kawakami, Akihiko, et al.
Publicado: (2022)

Comparison of US and EU Prices for Orphan Drugs in the Perspective of the Considered US Orphan Drugs Act Modifications and Discussed Price-Regulation Mechanisms Adjustments in US and European Union
por: Żelewski, Paweł, et al.
Publicado: (2022)

Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts
por: Jarosławski, Szymon, et al.
Publicado: (2011)

Systematic review of available evidence on 11 high-priced inpatient orphan drugs
por: Kanters, Tim A, et al.
Publicado: (2013)

Why “American Patients First” is likely to raise drug prices outside of the United States
por: Dabbous, Monique, et al.
Publicado: (2019)

Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending
por: WOUTERS, OLIVIER J., et al.
Publicado: (2017)

Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices
por: Dane, Aniek, et al.
Publicado: (2023)

Key drivers for market penetration of biosimilars in Europe
por: Rémuzat, Cécile, et al.
Publicado: (2017)

On the association between SARS-COV-2 variants and COVID-19 mortality during the second wave of the pandemic in Europe
por: Jabłońska, Katarzyna, et al.
Publicado: (2021)

The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe
por: Kawalec, Paweł, et al.
Publicado: (2016)

Gene therapy randomised clinical trials in Europe – a review paper of methodology and design
por: Ilieva, Krassimira, et al.
Publicado: (2020)

A qualitative study on the views of experts on the social impact of the high-priced orphan drug nusinersen
por: Rosenberg, Sara, et al.
Publicado: (2023)

Pricing and Reimbursement Pathways of New Orphan Drugs in South Korea: A Longitudinal Comparison
por: Lee, Jong Hyuk
Publicado: (2021)

Pricing vaccines and drugs in Europe: worth differentiating?
por: Garattini, Livio, et al.
Publicado: (2020)

The Sertindole Safety Survey: A retrospective analysis under a named patient use programme in Europe
por: Lançon, Christophe, et al.
Publicado: (2008)

Non-profit drug research and development: the case study of Genethon
por: Jarosławski, Szymon, et al.
Publicado: (2018)

An analysis of orphan medicine expenditure in Europe: is it sustainable?
por: Mestre-Ferrandiz, Jorge, et al.
Publicado: (2019)

Orphans in the Market: The History of Orphan Drug Policy
por: Mikami, Koichi
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_f0c201n12ubmgcik4uo0d3eog3